Unique ID issued by UMIN | UMIN000014410 |
---|---|
Receipt number | R000015871 |
Scientific Title | Usefulness of Forward-Viewing Endoscopic Ultrasound Scope for the Gastrointestinal tract submucosal tumors less than 15mm. |
Date of disclosure of the study information | 2014/06/28 |
Last modified on | 2015/07/31 12:12:29 |
Usefulness of Forward-Viewing Endoscopic Ultrasound Scope for the Gastrointestinal tract submucosal tumors less than 15mm.
Usefulness of Forward-Viewing Endoscopic Ultrasound Scope for the Gastrointestinal tract submucosal tumors less than 15mm.
Usefulness of Forward-Viewing Endoscopic Ultrasound Scope for the Gastrointestinal tract submucosal tumors less than 15mm.
Usefulness of Forward-Viewing Endoscopic Ultrasound Scope for the Gastrointestinal tract submucosal tumors less than 15mm.
Japan |
gastrointestinal submucosal lesions
Gastroenterology |
Malignancy
NO
Previous report demonstrated endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) for gastrointestinal submucosal lesion (SML) is feasible and safe with high diagnostic yield. On the other hand, since it is difficult to perform EUS-FNA for small SML especially less than 15mm, almost small SMLs are observed without EUS-FNA. However, because SMLs include malignant lesions even though a tumor is small, it is desirable to perform EUS-FNA when possible. The aim of this study is to evaluate feasibility and safety of EUS-FNA using forward-viewing echoendoscope attached with a cap device to the tip of scope for the small SML.
Efficacy
rate of sampling, accuracy, and complication
Kind of used device
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1.A patient having SMT less than 15mm.
2.When the whole lesion can be observed with the forward-viewing echoendoscope, and a puncture route is secured, and can puncture it safely.
3.When EUS-FNA brings the information that is important to the treatment choice of the patient.
4.After having received enough explanation about inspection,the patient that understood enough, and a document agreement was provided.
5.Performance status does not have the limit in particular.
1.Blood disorder (hemoglobin <7.0 g/dL or platelet <100000/uL)
2.Renal disease (blood BUN> 25 mg/dL or blood creatinine> 2.0 mg/dL)
3.Liver disease (Child Pugh score> 6)
4.Extension of the solidification time(for warfarin potassium internal use or cirrhosis,Under 70 years old PT-INR> 3.0, 70 years old or more PT-INR>2.6)
5.Case to have serious complications to other organs.More than the three of the ASA classification(the dialysis patient is excluded)
6.Case not to be provided of Informed consent
7.In addition, the patient who judged the examination medical attendant to be inappropriate as a subject
10
1st name | |
Middle name | |
Last name | Akane Yamabe |
Fukushima Medical University Aizu Medical Center
Gastroenterology
21-2, Maeda, Tanisawa, Kawahigashi., Aizuwakamatsu, Japan
0242-75-2100
akaneko@fmu.ac.jp
1st name | |
Middle name | |
Last name | Akane Yamabe |
Fukushima Medical University Aizu Medical Center
Gastroenterology
21-2, Maeda, Tanisawa, Kawahigashi., Aizuwakamatsu, Japan
0242-75-2100
akaneko@fmu.ac.jp
Fukushima Medical University Aizu Medical Center
organization
Other
NO
2014 | Year | 06 | Month | 28 | Day |
Unpublished
Suspended
2013 | Year | 04 | Month | 01 | Day |
2013 | Year | 04 | Month | 01 | Day |
Without intervention, be the observational studies using samples.
A study period is from March, 2014 to July, 2014.
2014 | Year | 06 | Month | 28 | Day |
2015 | Year | 07 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015871